GlaxoSmithKline plc with ticker (LON:GSK) now has a potential downside of -4.1% according to Deutsche.
Deutsche set a target price of 1,500 GBX for the company, which when compared to the GlaxoSmithKline plc share price of 1,562 GBX at opening today (18/02/2022) indicates a potential downside of -4.1%. Trading has ranged between 1,191 (52 week low) and 1,737 (52 week high) with an average of 9,726,660 shares exchanging hands daily. The market capitalisation at the time of writing is £80,178,378,997.
GlaxoSmithKline PLC is a global healthcare company. The Company researches and develops a range of products in three primary areas: Pharmaceuticals, Vaccines and Consumer Healthcare. Its product formulations include tablets, creams/ointments, inhalers, injections, liquids and sterile products. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency virus (HIV), immuno-inflammation and oncology. Its Vaccines business has a portfolio of vaccines to help protect people from a range of diseases throughout their lives. Its vaccines tackle diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza. Its Consumer Healthcare business combines science and consumer insights to create everyday healthcare brands that consumers trust, and experts recommend for oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements.
GlaxoSmithKline plc -4.1% potential downside indicated by Deutsche
- Written by: Charlotte Edwards
Find more news, interviews, share price & company profile here for:
GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates.
GSK's Shingrix aims for FDA-approved prefilled syringe to simplify shingles vaccination, enhancing convenience for healthcare providers.
GSK's ADC GSK5764227 gains FDA Breakthrough Therapy status for treating relapsed or refractory osteosarcoma, addressing critical unmet medical needs.
GSK's Nucala has been approved in China as an add-on treatment for CRSwNP, marking the first anti-IL-5 therapy for adults with this chronic condition.
GSK reports success in phase III trial of Zejula and Jemperli for advanced ovarian cancer, achieving significant progression-free survival improvement.
